(Pharmamar) PharmaMar (MSE:PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for Aplidin® (plitidepsin) for the indication of relapsed and refractory multiple myeloma.
(Pharmamar) PharmaMar (MSE:PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for Aplidin® (plitidepsin) for the indication of relapsed and refractory multiple myeloma.
We bring you the latest science news from best research centers and universities around the world. Check our website.
© 2023 Scienmag- Science Magazine: Latest Science News.
© 2023 Scienmag- Science Magazine: Latest Science News.